Global Marfan Syndrome Clinical Trials Review, H2 2021 Report Featuring A. Menarini Industrie Farmaceutiche Riunite Srl, Merck & Co, & Novartis –

November 25, 2021 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Marfan Syndrome – Global Clinical Trials Review, H2, 2021” clinical trials has been added to’s offering.

This report provides an overview of Marfan Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Marfan Syndrome.

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.


  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  1. Report Guidance
  2. Clinical Trials Report Coverage
  3. Clinical Trials by Region
  4. Clinical Trials and Average Enrollment by Country
  5. Marfan Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*
  6. Top Five Countries Contributing to Clinical Trials in Europe
  7. Top Countries Contributing to Clinical Trials in North America
  8. Clinical Trials by G7 Countries: Proportion of Marfan Syndrome to Genetic Disorders Clinical Trials
  9. Clinical Trials by Phase in G7 Countries
  10. Clinical Trials in G7 Countries by Trial Status
  11. Clinical Trials by Phase
  12. Clinical Trials by Trial Status
  13. Clinical Trials by End Point Status
  14. Clinical Trials by Sponsor Type
  15. Prominent Sponsors
  16. Top Companies Participating in Marfan Syndrome Therapeutics Clinical Trials
  17. Clinical Trial Profile Snapshots
  18. Appendix

Companies Mentioned

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Merck & Co Inc
  • Novartis AG

For more information about this clinical trials report visit


Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900